Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

DBV Technologies SA Enters into Strategic Manufacturing Agreement with Sanofi SA


Tuesday, 5 Mar 2013 02:00am EST 

DBV Technologies SA announced that it entered into a strategic manufacturing agreement with Sanofi SA to produce Viaskin’s Active Pharmaceutical Ingredients (API), such as the peanut protein extract. Per the agreement, Sanofi will act as DBV’s Contract Manufacturing Organization (CMO). In this context, Sanofi will scale-up and validate the production process of Viaskin’s API and full supply at commercial scale. DBV will benefit from Sanofi’s knowledge of biologics development and manufacturing in the field of plant extraction and purification of therapeutic proteins to further develop Viaskin. 

Company Quote

78.91
0.29 +0.37%
1 Aug 2014